Retrieve available abstracts of 34 articles: HTML format
Single Articles
June 2025
ZHANG J, Wang S, Li T, Liu X, et al RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand
combinations in advanced non-small cell lung cancer: a network meta-analysis.
J Natl Cancer Inst. 2025 Jun 6:djaf132. doi: 10.1093. PubMed
May 2025
MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al Association of radiation-induced normal tissue toxicity with a high genetic risk
for rheumatoid arthritis.
J Natl Cancer Inst. 2025;117:1018-1026. PubMedAbstract available
March 2025
ZHOU P, Cui J, Sun R, Liu X, et al RE: Racial and socioeconomic disparities in non-small cell lung cancer molecular
diagnostics uptake.
J Natl Cancer Inst. 2025 Mar 27:djaf081. doi: 10.1093. PubMed
MILDER CM, Cahoon EK, Schonfeld SJ, Preston DL, et al Sex-specific radiation-associated lung cancer mortality risks as impacted by
smoking among US radiologic technologists.
J Natl Cancer Inst. 2025 Mar 20:djaf064. doi: 10.1093. PubMedAbstract available
NOGUEIRA LM, Yabroff KR, Yates E, Shultz JM, et al Facility exposure to wildfire disasters and hospital length of stay following
lung cancer surgery.
J Natl Cancer Inst. 2025 Mar 11:djaf040. doi: 10.1093. PubMedAbstract available
February 2025
HU P, Prorok PC, Katki HA Design of randomized controlled trials to estimate cancer-mortality reductions
from multicancer detection screening.
J Natl Cancer Inst. 2025;117:303-311. PubMedAbstract available
January 2025
KANAYA N, Seddiq W, Chen KS, Kajiwara Y, et al Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in
immunosuppressive leptomeningeal brain metastasis.
J Natl Cancer Inst. 2025 Jan 22:djaf006. doi: 10.1093. PubMedAbstract available
GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al Pan-cancer genomic analysis reveals FOXA1 amplification is associated with
adverse outcomes in non-small cell lung, prostate, and breast cancers.
J Natl Cancer Inst. 2025;117:188-197. PubMedAbstract available
TUMINELLO S, Turner WM, Untalan M, Ivic-Pavlicic T, et al Racial and socioeconomic disparities in non-small cell lung cancer molecular
diagnostics uptake.
J Natl Cancer Inst. 2025;117:112-119. PubMedAbstract available
November 2024
GOMEZ SL, DeRouen M, Chen MS Jr, Wakelee H, et al Elevated risk of lung cancer among asian American females who have never smoked:
an emerging cancer disparity.
J Natl Cancer Inst. 2024 Nov 20:djae299. doi: 10.1093. PubMedAbstract available
SMITH RJ JR, Zollo R, Kalvapudi S, Vedire Y, et al Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy
with metformin.
J Natl Cancer Inst. 2024 Nov 19:djae295. doi: 10.1093. PubMedAbstract available
October 2024
KATKI HA, Prorok PC, Castle PE, Minasian LM, et al Increasing power in screening trials by testing control-arm specimens:
application to multicancer detection screening.
J Natl Cancer Inst. 2024;116:1675-1682. PubMedAbstract available
CHU X, Tian W, Ning J, Zhou R, et al Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced
NSCLC: a network meta-analysis.
J Natl Cancer Inst. 2024;116:1571-1586. PubMedAbstract available
September 2024
PROSPER AE, Lin Y, Aberle DR Lung cancer screening with low-dose computed tomography-where do we go from here?
J Natl Cancer Inst. 2024 Sep 16:djae197. doi: 10.1093. PubMed
August 2024
LIU Q, Medina HN, Koru-Sengul T, Rodriguez E, et al Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell
Lung Cancer.
J Natl Cancer Inst. 2024 Aug 21:djae199. doi: 10.1093. PubMedAbstract available
KATKI HA, Prorok PC, Castle PE, Minasian LM, et al Increasing power in screening trials by testing control-arm specimens:
application to multicancer detection screening.
J Natl Cancer Inst. 2024;116:1280-1287. PubMedAbstract available
June 2024
ZHANG EY, Cheung LC, Katki HA, Graubard BI, et al The risk and benefit profiles of US eligible lung cancer screening attendees vs.
non-attendees.
J Natl Cancer Inst. 2024 Jun 27:djae148. doi: 10.1093. PubMedAbstract available
HENDERSON LM, Durham DD, Gruden J, Pritchard M, et al Comparing characteristics of individuals screened for lung cancer with 2021
versus 2013 USPSTF recommendations.
J Natl Cancer Inst. 2024 Jun 24:djae141. doi: 10.1093. PubMedAbstract available
WU X, Zhang B RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression
predicts poor prognosis in resected non-small cell lung cancer.
J Natl Cancer Inst. 2024 Jun 8:djae130. doi: 10.1093. PubMed
TAKI T, Ishii G RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression
predicts poor prognosis in resected non-small cell lung cancer.
J Natl Cancer Inst. 2024 Jun 7:djae131. doi: 10.1093. PubMed
SCHUZ J, Kovalevskiy E, Olsson A, Moissonnier M, et al Cancer mortality in chrysotile miners and millers, Russian Federation: main
results (Asbest Chrysotile Cohort-Study).
J Natl Cancer Inst. 2024;116:866-875. PubMedAbstract available
UPRETY D, Seaton R, Hadid T, Mamdani H, et al Racial and socioeconomic disparities in survival among patients with metastatic
Non-Small cell lung cancer.
J Natl Cancer Inst. 2024 Jun 3:djae118. doi: 10.1093. PubMedAbstract available
March 2024
FUCITO LM, Palmer AM, Baldassarri SR A new perspective on mitigating lung cancer risks through smoking cessation and
reduction.
J Natl Cancer Inst. 2024 Mar 18:djae044. doi: 10.1093. PubMed
NAGASAKI Y, Taki T, Nomura K, Tane K, et al Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts
poor prognosis in resected non-small cell lung cancer.
J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093. PubMedAbstract available
February 2024
MOEN EL, Schmidt RO, Onega T, Brooks GA, et al Association between a network-based physician linchpin score and cancer patient
mortality: a SEER-Medicare analysis.
J Natl Cancer Inst. 2024;116:230-238. PubMedAbstract available
MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al Racial and ethnic disparities in genomic testing among lung cancer patients: a
systematic review.
J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093. PubMedAbstract available
January 2024
GUTIERREZ-TORRES DS, Kim S, Albanes D, Weinstein SJ, et al Changes in smoking use and subsequent lung cancer risk in the ATBC study.
J Natl Cancer Inst. 2024 Jan 25:djae012. doi: 10.1093. PubMedAbstract available
December 2023
SHIELS MS, Graubard BI, McNeel TS, Kahle L, et al Trends in smoking-attributable and smoking-unrelated lung cancer death rates in
the U.S., 1991-2018.
J Natl Cancer Inst. 2023 Dec 9:djad256. doi: 10.1093. PubMedAbstract available
BILLINGY NE, Tromp VNMF, Aaronson NK, Hoek RJA, et al Quality of life after patient-initiated vs physician-initiated response to
symptom monitoring: the SYMPRO-Lung trial.
J Natl Cancer Inst. 2023;115:1515-1525. PubMedAbstract available
ZUMSTEG ZS, Luu M, Rosenberg PS, Elrod JK, et al Global epidemiologic patterns of oropharyngeal cancer incidence trends.
J Natl Cancer Inst. 2023;115:1544-1554. PubMedAbstract available
LU K, Wang HC, Tu YC, Chang CC, et al Suppressing c-FOS expression by G-quadruplex ligands inhibits
osimertinib-resistant non-small cell lung cancer.
J Natl Cancer Inst. 2023;115:1383-1391. PubMedAbstract available
EVANS JV, Suman S, Goruganthu MUL, Tchekneva EE, et al Improving combination therapies: targeting A2B-adenosine receptor to modulate
metabolic tumor microenvironment and immunosuppression.
J Natl Cancer Inst. 2023;115:1404-1419. PubMedAbstract available
September 2023
KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al Circulating proteome for pulmonary nodule malignancy.
J Natl Cancer Inst. 2023;115:1060-1070. PubMedAbstract available